STAT July 12, 2024
Hello! Today, we talk about an Illumina competitor’s newest influx of funding, Adam weighs in on Pfizer’s plan for a once-a-day GLP-1 pill, and more.
What analysts make of Pfizer’s new GLP-1 plans
From STAT’s Adam Feuerstein: Pfizer’s decision yesterday to move ahead with a once-daily GLP-1 pill for obesity was met with a mix of cautious praise and skepticism from Wall Street wags.
The oral drug, called danuglipron, belongs to the same class of injectable obesity medicines as Wegovy and Zepbound. Last December, Pfizer shelved a twice-daily version of the drug because its weight-loss and tolerability profile wasn’t competitive. Now, Pfizer said it has selected a “modified release formulation” of danuglipron that might allow for once-daily dosing, pending the...
Today's Sponsors
Today's Sponsor